PreprintAll rights reservedbioRxiv
Affinity Maturation Enables Dual Targeting of Cancer-Associated MUC1-Tn/STn and Drives Potent Tumor Control
- 1The Scripps Research Institute
Related
- Affinity-tuned anti-idiotypic masking enables protease-activatable HER2-targeting antibodies with an optimized masked-unmasked dynamic range.
- Targeting tumor-selective membrane-associated PCNA enables selective antibody-drug conjugate therapy.
- Affinity maturation of a single-domain antibody via rational mutagenesis informed by artificial intelligence
- Reviving low-affinity glycan-targeting CAR with combinatorial design
- A UCP1-IRES-Cre knock-in mouse enables specific brown adipocyte targeting without CNS off-target expression
BibTeX
@misc{j2026affinity,
title = {{Affinity Maturation Enables Dual Targeting of Cancer-Associated MUC1-Tn/STn and Drives Potent Tumor Control}},
author = {J. YE and X. Zhu and H. Lu and J. Coppola and D. Zhang and Y. Tian and Z. Yang and S. Chung and L.-A. Cui and J. Zhi and L. Wen and J. Jeff Xi and I. A. Wilson and J. Jardine and P. Wu},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.22.761102},
url = {https://www.biorxiv.org/content/10.64898/2026.10.22.761102v1},
}
RIS
TY - UNPB
TI - Affinity Maturation Enables Dual Targeting of Cancer-Associated MUC1-Tn/STn and Drives Potent Tumor Control
AU - J. YE
AU - X. Zhu
AU - H. Lu
AU - J. Coppola
AU - D. Zhang
AU - Y. Tian
AU - Z. Yang
AU - S. Chung
AU - L.-A. Cui
AU - J. Zhi
AU - L. Wen
AU - J. Jeff Xi
AU - I. A. Wilson
AU - J. Jardine
AU - P. Wu
PY - 2026
DA - 2026/10/22
PB - bioRxiv
DO - 10.64898/2026.10.22.761102
UR - https://www.biorxiv.org/content/10.64898/2026.10.22.761102v1
ER -